K213464 is an FDA 510(k) clearance for the HemosIL Liquid Anti-Xa. Classified as Assay, Heparin (product code KFF), Class II - Special Controls.
Submitted by Instrumentation Laboratory CO (Bedford, US). The FDA issued a Cleared decision on October 4, 2022 after a review of 341 days - an unusually long review period, suggesting complex equivalence evaluation.
This device falls under the Hematology FDA review panel, regulated under 21 CFR 864.7525 - the FDA hematology device framework. As a Special 510(k), this submission covers a manufacturer modification to an existing cleared device rather than a new device introduction.
Device pattern: Iterative device modification. Elevated predicate reliance profile. This Special 510(k) clearance confirms that the manufacturer's modifications remained within the established regulatory envelope of the original cleared device.